Evidence map›Paper›PMID 31019847›Full record

ArticleTranslational vision science & technology2019

A Workshop on Measuring the Progression of Atrophy Secondary to Stargardt Disease in the ProgStar Studies: Findings and Lessons Learned.

Ann-Margret Ervin, Rupert W Strauss, Mohamed I Ahmed, David Birch, Janet Cheetham, Frederick L Ferris, Michael S Ip, Glenn J Jaffe, Maureen G Maguire, Etienne M Schönbach and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational vision science & technology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 41 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. The Importance of Natural History Studies in Inherited Retinal Diseases.Cold Spring Harbor perspectives in medicine · 2023
    Review
  9. Article
  10. Structural evaluation in inherited retinal diseases.The British journal of ophthalmology · 2021
    Review
  11. Observational
  12. Stargardt disease: Multimodal imaging: A review.Clinical & experimental ophthalmology · 2021
    Review
  13. Review
  14. Article
  15. Clinical Perspectives and Trends: Microperimetry as a Trial Endpoint in Retinal Disease.Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde · 2021
    Review
  16. Observational
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 10 institutions in 4 countries.

Ann-Margret ErvinWilmer Eye Institute, The Johns Hopkins School of Medicine, Johns Hopkins University, Baltimore, MD, USA.
Rupert W StraussWilmer Eye Institute, The Johns Hopkins School of Medicine, Johns Hopkins University, Baltimore, MD, USA.
Mohamed I AhmedWilmer Eye Institute, The Johns Hopkins School of Medicine, Johns Hopkins University, Baltimore, MD, USA.
David BirchRetina Foundation of the Southwest, Dallas, TX, USA.
Janet CheethamFoundation Fighting Blindness Clinical Research Institute, Columbia, MD, USA.
Frederick L FerrisNational Eye Institute, National Institutes of Health, Bethesda, MD, USA.
Michael S IpDoheny Imaging Reading Center, Doheny Eye Institute, David Geffen School of Medicine at University of California Los Angeles, CA, USA.
Glenn J JaffeDepartment of Ophthalmology, Duke University School of Medicine, Durham, NC, USA.
Maureen G MaguireDepartment of Ophthalmology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Etienne M SchönbachWilmer Eye Institute, The Johns Hopkins School of Medicine, Johns Hopkins University, Baltimore, MD, USA.
SriniVas R SaddaDoheny Imaging Reading Center, Doheny Eye Institute, David Geffen School of Medicine at University of California Los Angeles, CA, USA.
Sheila K WestWilmer Eye Institute, The Johns Hopkins School of Medicine, Johns Hopkins University, Baltimore, MD, USA.
Hendrik P N SchollWilmer Eye Institute, The Johns Hopkins School of Medicine, Johns Hopkins University, Baltimore, MD, USA.
ProgStar Study Group
Johns Hopkins University · USJohns Hopkins Medicine · USDoheny Eye Institute · USDuke University · USFoundation Fighting Blindness · USNational Institutes of Health · USRetina Foundation of the Southwest · USUniversity of Basel · CHUniversity of California, Los Angeles · USUniversity of Pennsylvania · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Progression of Atrophy Secondary to Stargardt Disease (ProgStar) studies were designed to measure the progression of Stargardt disease through the use of fundus autofluorescence imaging, optical coherence tomography, and microperimetry. The overarching objectives of the studies were to document the natural course of Stargardt disease and identify the most appropriate clinical outcome measures for clinical trials assessing the efficacy and safety of upcoming treatments for Stargardt disease. A workshop organized by the Foundation Fighting Blindness Clinical Research Institute was held on June 11, 2018, in Baltimore, MD, USA. Invited speakers discussed spectral-domain optical coherence tomography, fundus autofluorescence, and microperimetry methods and findings in the ProgStar prospective study. The workshop concluded with a panel discussion of optimal endpoints for measuring treatment efficacy in Stargardt disease. We summarize the workshop presentations in light of the most current literature on Stargardt disease and discuss potential clinical outcome measures and endpoints for future treatment trials.

Indexed as

fundus autofluorescencemicroperimetrynatural historyoptical coherence tomographyStargardt

Identifiers

PMID31019847
PMCPMC6469878
OpenAlexW2937301524

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.